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Abstract
Objectives—To determine long-term effects on substance use and substance use disorder
(SUD), up to 8 years after childhood enrollment, of the randomly assigned 14-month treatments in
the multisite Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity
Disorder (MTA; n=436); to test whether (a) medication at follow-up, (b) cumulative
psychostimulant treatment over time, or (c) both relate to substance use/SUD; to compare
substance use/SUD in the ADHD sample to the non-ADHD childhood classmate comparison
group (n=261).
Method—Mixed-effects regression models with planned contrasts were used for all tests except
the important cumulative stimulant treatment question, for which propensity score matching
analysis was used.
Results—The originally randomized treatment groups did not differ significantly on substance
use/SUD by the 8 year follow-up or earlier (M age = 17 years). Neither medication at follow-up
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(mostly stimulants) nor cumulative stimulant treatment was associated with adolescent substance
use/SUD. Substance use at all time points, including use of two or more substances and SUD,
were each greater in the ADHD than non-ADHD samples, regardless of sex.
Conclusions—Medication for ADHD did not protect from, nor contribute to, visible risk of
substance use or SUD by adolescence, whether analyzed as randomized treatment assignment in
childhood, as medication at follow-up, or as cumulative stimulant treatment over an 8 year follow-
up from childhood. These results suggest the need to identify alternative or adjunctive adolescent-
focused approaches to substance abuse prevention and treatment for boys and girls with ADHD,
especially given their increased risk for use and abuse of multiple substances that is not improved
with stimulant medication. Clinical trial registration information—Multimodal Treatment Study of
Children with Attention Deficit and Hyperactivity Disorder (MTA); http://clinical trials.gov/;
NCT00000388.
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Introduction
Risk of substance use or substance abuse or dependence disorders for children with
attention-deficit/hyperactivity disorder (ADHD) is a topic of substantial interest for
researchers, practitioners, and parents. Recent meta-analytic reviews of pertinent
longitudinal studies have reported moderately higher rates of substance abuse and
dependence by early adulthood for children with the disorder in relation to non-ADHD
comparison groups1,2. For example, although results across studies are heterogeneous,
children with ADHD are more than twice as likely as comparison peers to meet diagnostic
criteria for marijuana abuse or dependence by early adulthood2. The included studies do not,
however, provide data about the developmental course of substance use, and they tend to
emphasize diagnosis of substance abuse or substance dependence even for adolescents
whose addiction risk is often better measured by more developmentally sensitive,
continuous variables (e.g., frequency of alcohol use)3,4. Nevertheless, the results raise
important questions about factors, such as treatment history, that might affect ADHD-related
addiction vulnerability.
Although not the only evidence-based treatment for ADHD5, stimulants (e.g.,
methylphenidate, amphetamine) are the most commonly used and widely accessible
treatment, and prescription rates have increased markedly in recent years6. These
medications reliably decrease ADHD symptoms for over 80% of diagnosed children,
sometimes dramatically7,8. To the extent that symptoms of ADHD contribute to addiction
vulnerability, treatment with stimulant medication should theoretically decrease risk. Indeed,
a growing number of studies have shown that ADHD symptom persistence correlates with
substance use9–12. In other accounts, however, risk of substance abuse has been
hypothesized to increase for children medicated with stimulants13. This possibility,
potentially linked to the overlap in brain-based mechanisms for both addictive behaviors and
stimulant medication efficacy14, has been supported, with mixed results, in animal studies
showing an enhanced response to drugs of abuse following methylphenidate exposure15.
However, route of administration, relative dosages, developmental timing of medication
receipt, and limits of cross-species parallels (or lack thereof) complicate interpretation.
An early, small meta-analytic review of stimulant treatment and risk of substance abuse
reported a protective effect of medication use in adolescence and, to a lesser extent, in early
adulthood16. However, considering recently published studies, the accumulated data appear
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mixed. Some studies have found protective associations17–20; one reported predisposing
associations (i.e., more medication treatment, more substance use)13,21–22; and three
reported no association23–25. Barkley et al.25 reported one positive association for adulthood
cocaine use, which fell to non-significance after controlling for conduct disorder. A
retrospective chart review of a birth cohort in Rochester, MN, reported protection from
substance abuse by age 1826. Two other prospective longitudinal studies recently reported
(1) no association between years of stimulant treatment and substance use severity or
disorder for 16 to 22 year olds27 and (2) no association between childhood treatment with
stimulant medication (including course of medication) and SUD or tobacco use to age 2428.
Substantial and important variability in the methodologic features of these studies makes it
difficult to synthesize the findings. Samples vary considerably in age both within and across
studies, and age is a potentially confounding variable that is strongly related to both
treatment and substance use (W. Pelham, unpublished conference presentation, 2004
October). Compounding this problem is that most relevant research is based on sample sizes
of about 100, which can be insufficient for examining the association between stimulant
treatment and a variable that has a low to moderate frequency occurrence even in high risk
samples (i.e., substance abuse). For example, marijuana abuse and dependence peak at 5.6%
of 18–25 year olds nationally and are even less frequent at younger ages29. A few of the
relevant studies measured actual substance use21,24,25,27 whereas others relied on diagnostic
assessments of abuse or dependence (which, as mentioned earlier, may not identify teens on
a developmental trajectory toward abuse/dependence in adulthood). Studies also vary in
their operationalization of psychoactive treatment history, which has resulted in
fundamentally different questions being addressed across studies comprising a relatively
small literature.
The longitudinal follow-up of the children in the Multimodal Treatment Study of ADHD
(MTA) provides an opportunity to examine the association between ADHD treatment and
substance abuse with a large, diverse, narrow age-band sample recruited in childhood,
treated for 14 months in a randomized clinical trial, and followed prospectively with
substance use assessments through adolescence14. The randomized trial design of the MTA
in childhood (see below) provided partial protection from the influences of self-selection
into treatment at an age when medication treatment is at its peak30,31. In the first published
MTA report of substance use24 at three years after study baseline, no protective or
predisposing associations were found between substance use and early medication exposure,
measured as either (a) randomly assigned treatment or (b) proportion of days medicated in
the year leading up to the substance use assessment. However, substance use was nascent in
the first follow-up report, with limited opportunity to detect treatment effects because ages
ranged from 10 to 13 years. We now turn to the eight year follow-up (M age 16.8), when
substance use is more prevalent32.
Hence, one aim of the current study was to test the association between medication
treatment (both as randomly assigned during childhood and naturalistically used following
the clinical trial) and adolescent substance use/SUD by mean age 17. We opted for a three-
pronged approach to examine substance use/SUD as a function of (a) random assignment to
medication in childhood (at a mean age of 8.5); (b) concurrent medication use across the
multiple follow-up assessments; and most importantly, (c) duration of medication
(specifically psychostimulant treatment) from study entry to the eight year follow-up. Thus,
we expanded our analyses to consider putative long-term exposure effects of stimulant
medication that have been hypothesized to either protect children with ADHD from or
increase risk for substance use/SUD14. Although the initial randomization affected
subsequent parental choices about medication and therefore provided only partial protection
against the effects of confounding variables underlying natural selection into medication
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over time, initial group differences in medication use were lost by the three year follow-
up33. To control for these and other individual differences in propensity to medicate over
time, we selected an analytic approach—propensity score matching—favored for managing
the effects of confounding variables34. A similar propensity analysis was conducted at 3-
year follow-up for effects of medication on ADHD symptoms, without significant results35.
A second aim was to compare substance use/SUD at the 8 year follow-up between the
children with ADHD and an MTA-recruited and followed comparison group without
ADHD. This analysis tested an extension of our prior findings24 of ADHD-related risk for
substance use experimentation to heavier levels of use/SUD for the high school age range.
Polysubstance use is highly prevalent among teen substance users, but questions have arisen
about ADHD-related drug specialization, especially for tobacco because of its distinct
pharmacologic (stimulant) properties36; we examined use of other drugs by tobacco users.
We also tested whether our failure to find sex differences in early adolescent substance use24
would extend to this older age range. Because of the larger research literature on ADHD for
boys than for girls, it is not surprising that little research has been conducted on use/SUD in




The participants with ADHD in the MTA were 579 children with DSM-IV ADHD
combined type. Each of the six participating sites randomized 95 to 98 children to one of
four treatment groups: Medication Management (MedMgt), Behavior Therapy (Beh),
Combined MedMgt plus Beh (Comb), and Community Comparison (CC). At baseline
(pretreatment), participants were 7.0 to 9.9 years of age (M=8.5 years, SD=0.8 years). The
MTA recruitment strategy, procedures for diagnosing ADHD, treatment specifics, and
sample demographics have been described elsewhere41–46.
The children were reassessed at 3 and 9 months, at completion of the 14-month treatment
phase, at 24 and 36 months following randomization, and again at 6 and 8 years after
randomization. Participation rates dating from 14 months were 97%, 93%, 84%, 78%, and
75% of the original 579 enrolled, respectively. There were no significant differences in any
baseline characteristics between participants and non-participants for the 36-month
assessment33. However, children lost to the 8-year follow-up assessment, compared with
those retained, were more often male, had younger mothers, less-educated parents, lower
parent income, and parents more likely to have antisocial personality disorder at baseline
(p<.025 corrected for experimentwise-error). There were no significant differences on the
remaining sociodemographic or adversity variables (e.g., age, grade, ethnicity/race, parent
marital status, stable residency, on welfare, parent job loss, child health, birthweight) or on
baseline measures of intellect and achievement, parent and teacher report of ADHD and
oppositional defiant disorder (ODD) symptoms, parent-reported aggression and conduct
problems, parental diagnoses of mood, anxiety, alcohol, or other drug use disorders, or
randomized treatment group assignment. Mean ages at the 6- and 8-year follow-up
assessments were 14.9 (SD=1.0) and 16.8 (SD=1.0) years, respectively.
A local normative comparison group (LNCG, N=289) was recruited at 24 months to reflect
the local populations from which the ADHD sample was drawn. The LNCG children were
randomly selected from the same schools and grades and in the same sex proportions as the
children with ADHD. LNCG children were not excluded from recruitment because of
symptoms of ADHD, but those found to have diagnosable ADHD (n=31) were excluded
from the present analyses as we have done previously47. The assessment battery included
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the Diagnostic Interview Schedule for Children Version-IV (DISC-IV48) and teacher-
reported ratings of ADHD symptoms, which afforded examination of DSM-IV diagnoses
and ADHD symptom severity. The LNCG had the same entry criteria as the children with
ADHD except for ADHD diagnosis and age; they were matched to the age of the ADHD
sample at 24 months after randomization. Thus, data for the LNCG are available starting at
the 24-month assessment. At that time, average age of the LNCG (M=10.4 yrs, SD=1.08
yrs) did not differ significantly from that of the ADHD sample (t811=1.04, p=.36) at that
time point. The percentage of female subjects was similar in the LNCG (18.7%, n=54/289)
and the ADHD samples (19.7%, n=114/579, χ21=0.13, ns). The percentage of retained
LNCG participants by 6 and 8 years was 87% (252/289) and 90% (261/289), respectively.
The LNCG participants lost to the 8-year assessment had less stable residency and younger
mothers than those retained, but all other baseline variables were non-discriminating. LNCG
mean ages at the 6- and 8-year assessments were 14.5 (SD=1.2) and 16.6 years (SD=1.2),
respectively.
Measures
The substance use outcomes were measured at all interviews beginning with the 24 month
assessment. Use (e.g., consumption) of substances was measured separately from DSM
symptoms of abuse or dependence49. The primary analyses made use of two variables: a
single substance use variable and a single abuse/dependence variable, each composited
across substances. Secondary analyses explored substance-specific associations.
Substance Use—Substance use was assessed with a child/adolescent-reported
questionnaire50 adapted for the MTA. The measure included items for lifetime and current
(past 6 months) use of alcohol, cigarettes, chewing tobacco, marijuana, and other street
drugs. Also included were items for non-prescribed use or other misuse of psychoactive
medications, including stimulants. The measure was modeled after similar substance use
measures in longitudinal or national survey studies of alcohol and other drug use51–53 that
also rely on confidential youth self-report as the best source of data54. A National Institutes
of Health (NIH) Certificate of Confidentiality further strengthened the assurance of privacy.
Our primary substance use variable was a binary composite which allowed consideration of
multiple substance use classes simultaneously. Analysis of substance use as an ordinal
variable is a common approach—particularly for studying adolescents55. Substance use was
coded positive if any of the following behaviors, selected after examining distributions, were
endorsed as occurring in the participant’s lifetime: (1) drank alcohol (more than just a sip)
more than five times or drunk at least once; (2) smoked cigarettes or tried chewing tobacco
more than a few times; (3) used marijuana more than once; or (4) used inhalants,
hallucinogens, cocaine, or any of amphetamines/stimulants, barbiturates/sedatives, opioids/
narcotics without a prescription or misused a prescription (used more in quantity or more
often than prescribed). Each of the four types of substances, as well as daily use of tobacco
and the number of substance use classes endorsed (0, 1, 2 or more), were explored in
secondary analyses.
For the analysis of stimulant treatment duration in relation to substance use at the 8 year
follow-up, the primary outcome was number of substances used in the past six months, in
order to ensure that most stimulant treatment received would have preceded substance use.
Component variables included (1) “drunk” once or more or drank alcohol 3–4 times or
more; (2) one or more cigarettes/day in the past month (time frame exception specific to
tobacco); (3) marijuana two or more times; and (4) any other illicit drug use or prescription
medication misuse. Secondary analyses explored each class of substances separately.
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Substance abuse or dependence (SUD)—DSM-IV abuse or dependence was based
on a positive parent or child report with the Diagnostic Interview Schedule for Children Ver.
2.3/3.0 (DISC48) at the 6 and 8 year follow-up assessments. The DISC includes both
lifetime and past year diagnoses. The Diagnostic Interview Schedule-IV56 was used at the 8
year follow-up for 18+ year olds (n=111). SUD was defined as presence or absence of any
abuse or dependence in the lifetime (excluding tobacco dependence, due to differences in
the meaning of abuse/dependence for tobacco versus other substances). Additional analyses
explored SUD for alcohol, tobacco, and marijuana/other drugs (illicit or misuse of
prescription medications) separately.
For the analysis of stimulant treatment exposure over time in relation to substance use at the
8 year follow-up, the primary outcome variable was SUD in the past year for any substance
(excluding tobacco). Secondary analyses explored alcohol and marijuana/other drug use
disorders separately.
Psychoactive medication treatment—In addition to original randomized assignment
to treatment, two medication treatment variables were calculated from responses to the
Services for Children and Adolescents–Parent Interview,57,58 administered at all
assessments to collect a cumulative history of medication treatment since enrollment into the
study. Detailed information about the children’s psychoactive medication over the follow-up
period has been previously reported47. One variable was the proportion of days medicated
with psychoactive medications in the past year at each follow-up assessment. These
medications were predominantly stimulants but occasionally included others (atomoxetine,
guanfacine, and typical alternative medications such as clonidine and amitriptyline). A
second medication variable was calculated for the current study to reflect the cumulative
number of days stimulant-treated since enrollment into the study.
Statistical Approach
The analyses addressed (1) ADHD vs. LNCG group differences in substance use and SUD;
(2) prediction of substance use and SUD from original randomized treatment assignment,
including covariation with concurrent (past year) medication at each assessment; and 3)
prediction of substance use and SUD from cumulative days stimulant-treated since study
entry (using propensity score matching analysis).
The main analytic approach for (1) and (2) was generalized estimating equations (GEE)
analyses. As one method for mixed-effects regression with repeated measures, the GEE
analysis is an extension of the general linear model (for a relevant overview, see Hedeker
and Gibbons59, especially pp. 131–146). These analyses tested whether groups (subject
group; assigned treatment group) differed as a function of time. In contrast to traditional
repeated measures analysis of variance, mixed-effects regression allows inclusion of
subjects with complete data on covariates but partial data on the outcome variable. Thus, all
subjects with substance use data from at least one follow-up assessment between 24 months
and the 8 year follow-up were included in tests of group × time and treatment × time effects
(n=520 ADHD; n=258 LNCG). For question (2), the ADHD sample size was reduced to
n=515 because of missing data for medication use. We tested individual point-in-time
contrasts, treating group and time as fixed effects and the intercept as a random effect, to test
the significance of group differences overall and at each follow-up assessment. Because of
some variability in age at each assessment, age was controlled as a time-varying covariate
(as expected, it was always a statistically significant correlate). Power was sufficient (.80 or
higher) to detect small treatment group differences (effect size of .28 or larger) at p<.05 or
less. We used binary logit models for dichotomous outcomes and multinomial cumulative
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logit models for secondary analyses with ordinal count variable outcomes. We explored
whether participant sex moderated results.
For the ADHD group only, effects of treatment were tested with three orthogonal contrasts
following statistically significant treatment × time interactions (or for endpoint-only
analyses, following statistically significant main effects of treatment): Comb+MedMgt vs.
Beh+CC, termed the MTA Medication Algorithm effect; Comb vs. MedMgt, the
Multimodality effect; and Beh vs. CC, the Behavioral Substitution effect60. Consistent with
prior analyses24,47, we also tested an alternate set of planned contrasts in which behavioral
treatment rather than medication algorithm was the primary divider: Comb+Beh vs.
MedMgt+CC (Intensive Behavioral effect); Comb vs. Beh (Medication Addition effect); and
MedMgt vs. CC (Intensity of Medication effect). Covariates were site, age at each
assessment and proportion of days medicated in the past year (time-varying for repeated
measures analyses); and p-values > .025 are not reported as significant to adjust for alpha
inflation.
For (3), to test prediction of substance use and SUD from the number of days stimulant
treated since study entry, we used propensity score matching analyses for ordinal treatment
variables34. Propensity scores are calculated to represent each subject’s propensity (e.g.,
probability) to be stimulant-medicated over time as a function of baseline characteristics
(e.g., original randomly assigned treatment, ADHD symptom severity, parent education, and
family income). Participants with higher vs. lower stimulant medication exposure are
matched on the basis of these scores to statistically control for observed characteristics that
may influence the likelihood of natural selection into treatment over time. We used matched
pair analyses to compare the substance use and SUD variables between subjects with higher
vs. lower stimulant medication exposure.
Results
Medication Use Over Time
To explicate the medication variable, we first examined medication use over time. As
previously reported, proportion of days medicated in the past year declined over time to M=.
31(SD=.42) by the 8-year follow-up. In contrast, at 14 months when study-delivered
treatment ended, M (SD) was; .71 (.22) for Comb; .71 (.24) for MedMgt; .54 (.41) for CC; .
16 (.28) for Beh. At the 8 year follow-up, only 32.5% (132/406 with complete medication
data) were medicated over 50% of days in the past year (vs. 63.3% or 257/406 at 14
months). Treatment was still predominantly with stimulants (83%) or stimulants plus non-
stimulant treatment (8%). Cumulative number of days stimulant-treated since enrollment
into the study—with M (SD) =1,402 (985) days (M [SD] = 3.84 [2.70] yrs)—was
correlated .91 with cumulative dose, p<.01.
ADHD vs. LNCG
Substance use—There was a main effect of ADHD vs. LNCG group between the 24
month and 8 year follow-ups, χ2=20.59, p<.0001. Figure 1 depicts this finding as well as the
expected increase in substance use with time. There was a barely significant group × time
interaction, p=.05, indicating variable group effects with time. Group differences were
significant at each follow-up: 24 months, χ2(1)=12.54, p<.01; 36 months, χ2(1)=6.65, p=.
01; 6 years, χ2(1)=11.11; p<.01, 8 years, χ2=4.24, p=.04. However, the largest group
difference was at the 6 year follow-up, when 35% (n = 155/443) of ADHD and 19.5% (n =
44/226) of LNCG participants reported substance use. Results were similar for number of
substances used, with the ADHD vs. LNCG group difference greatest at the 6 year follow-
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up, with 17.8% (n=79/443) of ADHD and 8% (n=18/226) of LNCG participants reporting
use of 2 or more substances (see Fig.1).
Type of substance—ADHD/LNCG group differences were apparent for all substances.
There was a main effect of ADHD vs. LNCG group for alcohol use between the 24 month
and 8 year follow-ups, χ2(1)=5.99, p=.01, but no group × time interaction. There was a main
effect of ADHD vs. LNCG group for tobacco use, χ2(1)=23.98, p<.01 (group × time
interaction not tested because no LNCG subjects reported smoking at 24 or 36 months). Few
participants were sole tobacco users (i.e., did not also report other substance use), 3.6% of
ADHD (n=15/420) vs. 0% of LNCG. There were more daily smokers at 8 years for ADHD,
16.7%, than for LNCG, 7.9%, χ2(1)=10.58, p<.01. There was a main effect of ADHD vs.
LNCG group for marijuana and other drug use, χ2(1)=16.47, p<.01, but no group × time
interaction. Figure 2 shows the expected age-related increases in substance use and the high
prevalence of alcohol and marijuana use for both groups at mean age 17. The bar graphs also
illustrate the relatively stronger contribution of tobacco and marijuana use to the ADHD vs.
LNCG group differences.
Rates of illicit drug use other than marijuana, including misuse of prescription medications,
were low and not significantly different by group. At the 8 year follow-up, the following
categories of substance use had base rates below 5%: amphetamines/stimulants, barbiturates/
sedatives, opioids/narcotics, inhalants, hallucinogens/psychedelics, and cocaine. These rates
included misuse (more use than prescribed or use without a prescription) of amphetamine/
stimulant medications for the ADHD (8/422, 1.9%) and LNCG (4/230, 1.7%) groups.
SUD—There was a main effect of group (ADHD vs. LNCG) on SUD, but no main effect of
time or group × time interaction. The group effect was statistically significant at 6 years,
χ2(1)=11.01, p<.01, but not at 8 years, χ2(1)=1.45, p=.23 (for rates, see Table 1).
Type of SUD—For alcohol abuse or dependence, there was no main effect of group, no
main effect of time, and no group × time interaction (for all rates, see Table 1). For
marijuana/other drug abuse or dependence, there was a main effect of group, but no main
effect of time and no group × time interaction. For nicotine dependence, there was a main
effect of group, but no main effect of time. In each case, the ADHD group had greater use.
There were too few nicotine dependence diagnoses among LNCG subjects to evaluate a
group by time interaction.
Sex—There was no main effect of sex, χ2(1)=.49, p=.49, and no sex by ADHD group
interaction, χ2(1)=.30, p=.59 for substance use. Results were parallel for number of
substances used, χ2(1)=.82, p=.37, and χ2(1)=.19, p=.66, respectively. There was a main
effect of sex for SUD, χ2(1)=4.21, p=.04, with more boys (17.9%) than girls (11.5%)
meeting diagnostic criteria. There was no group × sex interaction, χ2(1)=.02, p=.89.
Associations with Treatment: Randomly Assigned in Childhood and Naturalistic
Medication Use at each Follow-Up Assessment
Substance use—Neither treatment assignment at baseline nor proportion of days
medicated in the past year was significantly associated with substance use at any follow-up
assessment. For the orthogonal treatment contrasts, ps ranged from .03 to .96 (with an
average p=.52). The overall effect of the proportion of days medicated was not significant,
p=.68, and there were no statistically significant medication × time interactions. Removal of
the treatment group assignment variables (because of their correlation with medication
treatment at the earlier assessments) did not change the pattern of results (p=.59). Results
were similar for number of substances used.
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Type of substance—There were no statistically significant associations between original
randomized treatment assignment and alcohol use, average p=.60, tobacco use, average p=.
26, or marijuana/drug use, p=.58 (ps ranged from .07 to .99). There were also no
associations between these variables and ADHD medication use at each assessment for
alcohol use, average p=.55, for tobacco use, average p=.25, or for marijuana/drug use,
average p=.46 (ps ranged from .22 to .82).
SUD—Neither randomized treatment assignment nor proportion of days medicated in the
past year was a statistically significant predictor (correlate) of SUD at the 6 and 8 year
assessments. Across all orthogonal treatment contrasts and across assessments, the average
p-value for the treatment group comparisons was p=.51 (range = .03 to .89). The association
between proportion of days medicated and SUD was also not statistically significant, p=.37,
and did not interact with assessment point, p=.48. There were no statistically significant
associations for any specific type of SUD (alcohol, marijuana/drug) or for nicotine
dependence.
Cumulative Psychostimulant Treatment and Substance Use/SUD at 8 years
For the propensity score matching analyses, and following Lu et al.,34 the distribution of
days that participants had been stimulant treated since baseline was divided into five ordinal
groups using quintile cut points. Using an ordinal logit model, quintile group membership
was regressed on 36 variables selected for their potential to predict stimulant treatment.
These included demographics (e.g., parent education and income; marital status; child sex),
receipt of medication or school assistance prior to study enrollment, ADHD symptom
severity (parent and teacher report), parent-reported impairment, other behavior problems
(e.g., parent and teacher ratings of oppositionality and aggression), social skills ratings by
parent and teacher, achievement test scores and IQ estimate, parental psychopathology
(mood, anxiety, alcohol, or drug use disorder), and original randomly assigned treatment
group (references for these variables are reported elsewhere45). A propensity score was
produced for each participant, estimated from baseline characteristics, as an index of the
likelihood of receiving more or fewer days of stimulant treatment between baseline and the
8 year follow-up. Participants were subsequently matched in pairs to minimize their
differences in propensity scores and maximize their differences in days of stimulant
treatment. These matched pairs produced two groups distinguished by more versus fewer
days treated. As planned, the groups differed significantly in days stimulant treated, M =
2071.10, SD = 728.87, versus M = 763.08, SD = 765.00, p<.01, but not in any of the 36
baseline variables, all ps > .10; average p-value =.70.
Matched pair analyses were performed for each of the primary (composited number of
substances used; any SUD excluding nicotine dependence) and secondary (alcohol;
marijuana; cigarettes; SUD for alcohol and SUD for marijuana/other drugs) variables. There
were no statistically significant associations for any of these variables. For the primary
outcomes, the Wilcoxon signed-rank test for number of substances used was z = −.34, p=.
73; McNemar’s chi-square test for any SUD was χ2(1)=.44, p=.62. For the exploratory
analyses: alcohol use, z=.42, p=.68; cigarettes, z=−.54, p=.59; marijuana, z=.45, p=.65,
alcohol abuse or dependence, χ2(1)=.00, p=1.00; marijuana or other drug abuse or
dependence, χ2(1)=1.29, p=.35.
Discussion
The current study first tested the hypothesis that children with combined type ADHD have
increased risk of substance use and SUD in adolescence. We found a significantly higher
prevalence of substance use by adolescents with, versus former classmates without, ADHD
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histories. Overall group differences for any SUD (DSM-IV abuse or dependence) were also
observed, but these occurred at comparatively lower rates and only at certain ages—for
marijuana and nicotine only—highlighting the importance of measuring levels of certain
types of substance use in adolescence that may foreshadow later SUD in adulthood. The
multi-site nature of the MTA sample, including demographic diversity (e.g., 20% female)
and other unique sample features (see below), underscores for the first time the significance
of the substance abuse risk for both boys and girls with childhood ADHD. This finding
renders all the more important our examination of treatment effects on substance use/SUD
risk. Across all analyses, we found no associations to suggest either harm or benefit from
medication (mostly stimulant) treatment in regard to rates of adolescent substance use or
SUD. As this is the first study to include a period of randomized assignment to treatment
and the first to consider a large number of potential confounding variables, these findings
are the strongest test to date of the association between medication for ADHD and
adolescent substance abuse.
About one-third of the MTA sample fell into a high risk group for adult substance abuse
based on their repeated use of substances as adolescents. At the six year follow-up (mean
age of 15), group differences were greatest with 35% of the ADHD versus 20% of the
LNCG (non-ADHD) groups reporting use of one or more substances. We also detected
group differences in SUD at the six year follow-up, but for fewer participants, which may
explain other smaller studies’ failure to find statistically significant group differences in
adolescent SUD50,61. A large body of research has shown that substance use at a young age
is prognostic of later abuse/dependence in adulthood62,63.
Marijuana and tobacco use most clearly distinguished the ADHD from LNCG groups. Only
a few longitudinal studies of children diagnosed with ADHD have examined marijuana use,
as opposed to abuse/dependence, and the results have been mixed50,64–65. In the current
study, a third of the children with ADHD (32%) had used marijuana more than once by the 8
year follow-up (mean age of 17) versus 24% of the LNCG. These high rates for both groups
reflect the increasing use of marijuana by teens in the United States66 but they also indicate
a relatively higher risk of marijuana use for teens with ADHD histories. This risk was barely
visible in early adolescence but picked up speed by the 6 year follow-up assessment (mean
age of 15). At this age, nearly one-fifth of our participants with ADHD histories reported
marijuana use more than once, indicating that this outcome variable should be directly
targeted for future research. Marijuana use at a young age has been associated with a host of
negative cognitive sequelae such as neurocognitive decrements, decreased academic
achievement, and poor physical health67–72. Given the long-term impact of childhood
ADHD on educational, occupational, and psychosocial outcomes of adulthood9, early and
chronic marijuana use has the potential to significantly undermine later adult
accomplishments for this population.
Tobacco use (mostly cigarette smoking) was strongly associated with childhood ADHD.
Nearly a quarter (24%) of the ADHD sample had smoked cigarettes or used other forms of
tobacco more than a few times by the 8 year follow-up, and 17% were already daily
smokers. These are high rates compared to both the LNCG (8% were daily cigarette users)
and to daily smoking rates for high school students nationally, 11.2%73. Combined with
other reports of high rates of daily smoking from single site samples9,74, these findings
suggest that the MTA children are headed toward a previously projected4 doubling of the
19.3% adulthood prevalence of smoking currently found in the USA75. Cigarette use that
begins in adolescence is associated with an increased likelihood of nicotine addiction into
adulthood and with a lower likelihood of successful quitting76,77. Adolescent cigarette use is
also associated with use and abuse of other drugs78—a finding strongly supported by the
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current data for both the ADHD and non-ADHD groups. In fact, we found extremely few
adolescents who reported using only cigarettes.
Assignment to study treatments in childhood did not predict any high school-aged
substance-related outcomes. This result parallels our previously reported failure to find
treatment group differences for any of the other 24 symptom, behavioral, and functioning
(e.g., arrests, psychiatric hospitalizations, etc.) variables examined at the same age48. Many
of these variables (e.g., impulsivity, conduct problems, academic achievement) are long-
established predictors of substance use for teens in the general population79–81 and in other
studies they correlate with substance use for adolescents with ADHD histories12,82,83. To
the extent that these variables were not differentially affected by assigned treatment group in
childhood47, it follows that substance use/SUD in adolescence should not be differentially
affected. Collectively, these findings are in stark contrast to the widely held belief that
starting treatment early (here, mean age of 8) will, in and of itself, change long-term
outcomes that also include SUD vulnerability. Instead, treatments found to be efficacious for
adolescent substance abuse84,85 may hold some promise for this population due to their
targeting of the same behavioral, academic, and familial/peer vulnerabilities known to
accompany adolescent ADHD.
Our findings did not provide any evidence that ADHD medication protects from, or
increases risk for, adolescent substance use or SUD. This finding held for recent medication
and for days cumulatively treated with stimulants. Unmeasured confounders may have been
operating due to the naturalistic follow-up study design, and we did not statistically control
for psychopathology and functioning at the follow-up assessments. However, we conducted
the most carefully controlled analysis to date using a statistical method (propensity score
matching analysis) that allowed consideration of multiple baseline factors that might
contribute to long-term medication treatment or termination. Moreover, our prior report that
medication at high school age does not relate to multiple indicators of symptoms and daily
functioning47 revealed that addition of these covariates was not indicated. Our findings
conflict with anecdotal clinical experience with long-term patients who appear to derive
benefit from continued medication. We speculate that these experiences reflect a subset of
well-monitored teens who, unlike the majority of our sample, continue to be accepting of
medication recommendations and other concurrent protective strategies and/or may have a
low risk profile for developing substance use.
The observed lack of associations between stimulant exposure over time and adolescent
substance use/SUD do not discount the possibility that brain-based changes in neural
mechanisms underlying addiction vulnerability are occurring as a function of prolonged
stimulant treatment. Volkow et al. recently demonstrated, for stimulant-naïve adults with
ADHD, an up-regulation of the dopamine transporter and decreased D2 receptor availability
in the striatum following one year of methylphenidate treatment86,87. Although
demonstrated with adults, these findings heighten concern about potential stimulant-related
adjustments in dopaminergic mechanisms pertinent to drug abuse vulnerability. On the other
hand, Castellanos et al. (2002) suggested neuroprotection from stimulant use in childhood
and adolescence for youth with ADHD88. Studies of differential responsivity to drug
challenges in adulthood as a function of prior stimulant treatment would be useful. In
adolescence, as in the present study, other factors that increase substance abuse risk, such as
parental and peer influences, may outweigh developing biological vulnerability.
The substance use/SUD outcomes for the MTA should be considered in the context of
several unique study features and limitations. All of the children in the MTA were diagnosed
with the combined type of DSM-IV ADHD, and generalization of study results should
generally not extend beyond this subtype. It is interesting that conduct disorder, a common
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comorbidity for the combined subtype that is also a strong proximal mediator of ADHD-
related substance use/SUD, was infrequent. Compared to other clinic-based longitudinal
studies of ADHD, for which CD rates range from 25% to 30% for boys64,83 and 18% to
23% for girls38,39, the MTA rate of 8% at the 8 year assessment47, and even the rate of 14%
at baseline44, is low. The sample recruitment that included, in addition to psychiatric clinics,
pediatrician offices and school settings41 may have contributed to this finding89). Our
follow-up assessments, which relied on self-report and often with two-year windows, may
have missed episodes of substance use and rates may be underestimated. Similarly, the
precision of our treatment data relies on the accuracy of parent recall at each assessment
which no doubt includes some degree of error.
Thus, children with ADHD have increased risk of substance use, in particular tobacco and
marijuana, against a backdrop of high rates of alcohol use for all teens, and our standard
treatments (short-term psychosocial, medication) for ADHD have not, to date, countered this
risk. Given the ubiquity of medicinal treatment for ADHD, and our failure to find relations
between ADHD medication treatment and adolescent substance use/SUD, the findings argue
for additional research on neurobiological and psychosocial factors that fuel the
vulnerability and can inform the types of treatment so urgently needed.
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Proportion of Participants Using Substances (by Number of Substances) from the 24-month
through 8-year Follow-up Assessments. ADHD = Attention-Deficit/Hyperactivity Disorder;
LNCG = Local Normative Comparison Group.
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Percent of Participants Reporting Alcohol, Tobacco, Marijuana, and Other Drug Use at Each
of the 6- and 8-year Follow-up Assessments. ADHD = Attention-Deficit/Hyperactivity
Disorder; LNCG = Local Normative Comparison Group.
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